facilities of $5.8 million and $0.5 million in the third quarter of
2008 and 2007 GAAP results, respectively. The $5.8 million charge
for the three months ended September 30, 2008 included $1.8 million
charged to cost of sales, $0.3 million charged to research and
development, $3.4 million charged to selling, general and
administrative and $0.3 million charged to interest expense. The
$0.5 million charge for the third quarter of 2007 includes $0.3
million charged to research and development and $0.2 million charged
to selling, general and administrative. These charges have been
excluded from net income or loss because they have a significant
impact on results yet do not occur on a consistent or regular basis
in the Company's business.
(d) Compensation costs of $7.0 million and $3.3 million associated with
stock-based compensation expense in the third quarter of 2008 and
2007 GAAP results, respectively, including $0.4 million and $0.1
million charged to cost of sales, $1.1 million and $0.6 million
charged to research and development and $5.5 million and $2.5
million charged to selling, general and administrative, in the
(e) A write-off in the amount of $6.3 million during the third quarter
of 2007, relating to inventory write-ups recorded in connection with
the acquisitions of Biosite, Inc. and Cholestech Corp. during the
second and third quarters of 2007.
(f) Purchase of in-process research and development during the third
quarter of 2007 includes a write-off of $169.0 million associated
with the value of in-process research and development costs incurred
in connection with our acquisition of Biosite, Inc.
|SOURCE Inverness Medical Innovations, Inc.|
Copyright©2008 PR Newswire.
All rights reserved